Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when

References

• Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol.18(3), 581–592 (2007).
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Yonover PM. The role of radical nephrectomy in metastatic renal cell carcinoma. Semin. Urol. Oncol.19(2), 98–102 (2001).
   PubMedGoogle Scholar
• Russo P, O’Brien MF. Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy. Urol. Clin. North Am.35(4), 679–686 (2001).
   Google Scholar
• Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med.345(23), 1655–1659 (2001).
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Garin A, Van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet358(9286), 966–970 (2001).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bukowski RM, Figlin RA et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer113(7), 1552–1558 (2008).
   PubMed Web of Science ®Google Scholar
• Wood CG. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin. Cancer Res.13(2 Pt 2), 697s–702s (2001).
   Google Scholar
• Pantuck AJ, Belldegrun AS, Figlin RA. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy? Clin. Cancer Res.13(2 Pt 2), 693s–696s (2007).
   Google Scholar
• Wood CG, Margulis V. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer115(Suppl. 10), 2355–2360 (2009).
   PubMedGoogle Scholar
• Powles T, Blank C, Chowdhury S et al. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur. Urol.60(3), 448–454 (2011).
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol.171(3), 1071–1076 (2004).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27(22), 3584–3590 (2009).
   PubMed Web of Science ®Google Scholar
• van der Veldt AA, Meijerink MR, van den Eertwegh AJ et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin. Cancer Res.14(8), 2431–2436 (2008).
   PubMed Web of Science ®Google Scholar
• Crispen PL, Blute ML. Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma. Curr. Urol. Rep.13(1), 38–46 (2011).
   Google Scholar
• Richey SL, Culp SH, Jonasch E et al. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann. Oncol.22(5), 1048–1053 (2011).
   PubMed Web of Science ®Google Scholar
• Zini L, Capitanio U, Perrotte P et al. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology73(2), 342–346 (2009).
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Xie W, Kollmannsberger C et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J. Urol.185(1), 60–66 (2011).
   PubMed Web of Science ®Google Scholar
• Warren M, Venner PM, North S et al. A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Can. Urol. Assoc. J.3(4), 281–289 (2001).
   Google Scholar
• Aben KK, Heskamp S, Janssen-Heijnen ML et al. Better survival in patients with metastasised kidney cancer after nephrectomy: a population-based study in the Netherlands. Eur. J. Cancer47(13), 2023–2032 (2011).
   PubMedGoogle Scholar
• Bex A, Jonasch E, Kirkali Z et al. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur. Urol.58(6), 819–828 (2010).
   PubMed Web of Science ®Google Scholar
• Thomas AA, Rini BI, Lane BR et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J. Urol.181(2), 518–523 (2009).
   PubMed Web of Science ®Google Scholar
• Bex A, van der Veldt AA, Blank C, Meijerink MR, Boven E, Haanen JB. Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. Acta Oncol.49(4), 520–523 (2010).
   PubMed Web of Science ®Google Scholar
• Johannsen M, Staehler M, Ohlmann CH et al. Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy. Ann. Oncol.22(3), 657–663 (2011).
   PubMed Web of Science ®Google Scholar
• Sadeghi S, Albiges L, Wood LS et al. Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome. Cancer doi:10.1002/cncr.26666 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Griffioen AW, Vyth-Dreese FA. Angiostasis as a way to improve immunotherapy. Thromb. Haemost.101(6), 1025–1031 (2009).
   PubMedGoogle Scholar
• Lindenberg JJ, Fehres CM, van Cruijsen H, Oosterhoff D, de Gruijl TD. Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity. Immunotherapy3(1), 77–96 (2011).
   PubMed Web of Science ®Google Scholar
• Blank C, Kuball J, Voelkl S et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int. J. Cancer119(2), 317–327 (2006).
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Meng Y, Blank C et al. Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev.213, 131–145 (2006).
   PubMed Web of Science ®Google Scholar
• Thompson RH, Kuntz SM, Leibovich BC et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res.66(7), 3381–3385 (2006).
   PubMed Web of Science ®Google Scholar
• Krambeck AE, Thompson RH, Dong H et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc. Natl Acad. Sci. USA103(27), 10391–10396 (2006).
   PubMed Web of Science ®Google Scholar
• Finke JH, Rini B, Ireland J et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin. Cancer Res.14(20), 6674–6682 (2008).
   PubMed Web of Science ®Google Scholar
• Desar IM, Jacobs JFM, Hulsbergen-vandeKaa CA et al. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int. J. Cancer129(2), 507–512 (2011).
   PubMedGoogle Scholar
• Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol.7(1), 41–51 (2007).
   PubMed Web of Science ®Google Scholar
• Ko JS, Rayman P, Ireland J et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res.70(9), 3526–3536 (2010).
   PubMed Web of Science ®Google Scholar
• Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int. Immunopharmacol.11(7), 856–861 (2011).
   PubMed Web of Science ®Google Scholar
• Lara PN Jr, Tangen CM, Conlon SJ, Flanigan RC, Crawford ED. Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. J. Urol.181(2), 512–516 (2001).
   Google Scholar
• Barbastefano J, Garcia JA, Elson P et al. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int.106(9), 1266–1269 (2010).
   PubMed Web of Science ®Google Scholar
• Pierorazio PM, McKiernan JM, McCann TR, Mohile S, Petrylak D, Benson MC. Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed. BJU Int.100(4), 755–759 (2007).
   PubMed Web of Science ®Google Scholar
• Kutikov A, Uzzo RG, Caraway A et al. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int.106(2), 218–223 (2010).
   PubMed Web of Science ®Google Scholar
• Abdollah F, Sun M, Thuret R et al. Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study. Ann. Surg. Oncol.18(10), 2988–2996 (2011).
   PubMed Web of Science ®Google Scholar
• O’Malley RL, Brewer KA, Hayn MH et al. Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible? Urology78(3), 595–600 (2011).
   PubMedGoogle Scholar
• Cloutier V, Capitanio U, Zini L et al. Thirty-day mortality after nephrectomy: clinical implications for informed consent. Eur. Urol.56(6), 998–1003 (2009).
   PubMed Web of Science ®Google Scholar
• Kassouf W, Sanchez-Ortiz R, Tamboli P et al. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience. Urology69(5), 835–838 (2007).
   PubMed Web of Science ®Google Scholar
• Bex A, van der Veldt AA, Blank C et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J. Urol.27(4), 533–539 (2009).
   PubMed Web of Science ®Google Scholar
• Maxwell NJ, Saleem Amer N, Rogers E, Kiely D, Sweeney P, Brady AP. Renal artery embolisation in the palliative treatment of renal carcinoma. Br. J. Radiol.80(950), 96–102 (2007).
   PubMedGoogle Scholar
• Leibovich BC, Cheville JC, Lohse CM et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J. Urol.174(5), 1759–1763 (2005).
   PubMed Web of Science ®Google Scholar
• Negrier S, Escudier B, Gomez F et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie. Ann. Oncol.13(9), 1460–1468 (2002).
   PubMed Web of Science ®Google Scholar
• Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J. Clin. Oncol.16(6), 2261–2266 (1998).
   PubMed Web of Science ®Google Scholar
• Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer117(13), 2873–2882 (2011).
   PubMed Web of Science ®Google Scholar
• Karam JA, Rini BI, Varella L et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J. Urol.185(2), 439–444 (2011).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol.17(8), 2530–2540 (1999).
   PubMed Web of Science ®Google Scholar
• Patil S, Figlin RA, Hutson TE et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann. Oncol.22(2), 295–300 (2011).
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Garcia JA, Elson P et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer110(3), 543–550 (2007).
   PubMed Web of Science ®Google Scholar
• Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol.27(34), 5794–5799 (2009).
   PubMed Web of Science ®Google Scholar
• Culp SH, Tannir NM, Abel EJ et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer116(14), 3378–3388 (2010).
   PubMed Web of Science ®Google Scholar
• You D, Jeong IG, Ahn JH et al. The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. J. Urol.185(1), 54–59 (2011).
   PubMed Web of Science ®Google Scholar
• Kassouf W, Sanchez-Ortiz R, Tamboli P et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J. Urol.178(5), 1896–1900 (2007).
   PubMed Web of Science ®Google Scholar
• Margulis V, Wood CG. Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical therapy? Eur. Urol.54(3), 480–492 (2008).
   Google Scholar
• Amin C, Wallen E, Pruthi RS, Calvo BF, Godley PA, Rathmell WK. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology72(4), 864–868 (2008).
   PubMed Web of Science ®Google Scholar
• Bex A, Blank C, Meinhardt W, van Tinteren H, Horenblas S, Haanen J. A Phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ. Urology78(4), 832–837 (2011).
   PubMedGoogle Scholar
• Cowey CL, Amin C, Pruthi RS et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J. Clin. Oncol.28(9), 1502–1507 (2010).
   PubMed Web of Science ®Google Scholar
• Hellenthal NJ, Underwood W, Penetrante R et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J. Urol.184(3), 859–864 (2010).
   PubMed Web of Science ®Google Scholar
• Jonasch E, Wood CG, Matin SF et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J. Clin. Oncol.27(25), 4076–4081 (2009).
   PubMed Web of Science ®Google Scholar
• Chapin BF, Delacroix SE Jr, Culp SH et al. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur. Urol.60(5), 964–971 (2011).
   PubMed Web of Science ®Google Scholar
• Powles T, Kayani I, Blank C et al. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann. Oncol.22(5), 1041–1047 (2011).
   PubMed Web of Science ®Google Scholar
• Abel EJ, Culp SH, Tannir NM et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur. Urol.59(1), 10–15 (2011).
   PubMed Web of Science ®Google Scholar
• Abel EJ, Culp SH, Tannir NM, Tamboli P, Matin SF, Wood CG. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur. Urol.60(6), 1273–1279 (2011).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med.356(2), 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Boleti E, Chowdhury S, Jones R, Crabb S, Sarwar N, Powles T. The safety and efficacy of pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer. Presented at: 2012 Genitourinary Cancers Symposium. San Francisco, CA, USA, 2–4 February 2012.
   Google Scholar
• Ljungberg B, Cowan NC, Hanbury DC et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur. Urol.58(3), 398–406 (2010).
   PubMed Web of Science ®Google Scholar
• Varela I, Tarpey P, Raine K et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature469(7331), 539–542 (2011).
   PubMed Web of Science ®Google Scholar
• Welti JC, Gourlaouen M, Powles T et al. Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene30(10), 1183–1193 (2011).
   PubMed Web of Science ®Google Scholar
• Dalgliesh GL, Furge K, Greenman C et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature463(7279), 360–363 (2010).
   PubMed Web of Science ®Google Scholar
• Stewart G, Berney D, Harrison D, Powles T. Proteomic analysis of pre- and post-sunitinib treated renal cancer tissue to assess tumor heterogeneity and differential protein expression. Presented at: 2012 Genitourinary Cancers Symposium. San Francisco, CA, USA, 2–4 February 2012 (2012).
   Google Scholar
• Bex A, Haanen J. Tilting the AXIS towards therapeutic limits in renal cancer. Lancet378(9807), 1898–1900 (2011).
   PubMedGoogle Scholar
• Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B, Sternberg CN. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit. Rev. Oncol. Hematol.77(1), 48–62 (2011).
   PubMed Web of Science ®Google Scholar
• Oudard S. More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus. Anticancer Res.30(12), 5223–5225 (2010).
   PubMedGoogle Scholar
• Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int.108(10), 1556–1563 (2011).
   PubMed Web of Science ®Google Scholar
• Amin A, Dudek A, Logan T et al. A Phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) in combination with sunitinib. J. Clin. Oncol.28(Suppl.), 15 (2010) (Abstract 4588).
   PubMedGoogle Scholar